GOLMePsA RCT early naive PsA Golimumab or PBO in addition to MTX+IM GCs No difference wk52 ACR20 GOL 76% PBO 55% MDA GOL 55% PBO 41% PBO arm received higher GC dose No new safety signal @RheumNow AbstOP0148 #EULAR2024 https://t.co/bj7YNXhssm